Stocktoria
iSpecimen Inc. ISPC
iSpecimen Inc. (ISPC) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.9M at a -543.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ISPC | iSpecimen Inc. | 3/9 | — | — | — |
| ONMD | OneMedNet Corp | 5/9 | — | — | — |
| ABSI | Absci Corp | 2/9 | -1.9 | — | — |
| VSBC | VITASPRING BIOMEDICAL CO. LTD. | 4/9 | — | — | — |
| BIAF | bioAffinity Technologies, Inc. | 3/9 | — | — | — |
| OABI | OmniAb, Inc. | 1/9 | 6 | — | -29.3% |
| NRC | NRC HEALTH | 3/9 | 0.03 | — | -4% |
About iSpecimen Inc.
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
FAQ
Is ISPC financially healthy?
iSpecimen Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does ISPC pay a dividend?
No, iSpecimen Inc. does not currently pay a dividend.
How profitable is ISPC?
In FY2025, iSpecimen Inc. had a net margin of -543.7% and a return on equity of -339.6%.
Is ISPC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on iSpecimen Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.